Digital Pathway - The Intersection of NASH and Cardiometabolic Diseases: Implications for Screening, Diagnosis, and Management
Non-alcoholic steatohepatitis (NASH) is a metabolic-based constellation of multiple organ pathology that overlaps with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. The sequelae of NASH, stemming from nonalcoholic fatty liver disease (NAFLD), has at the root of it, several of these cardiometabolic risk factors and existing cardiovascular disease. There seems to be an increasing confusion about NASH risk factors, screening, and treatment options, and perhaps, patients with cardiovascular and cardiometabolic risk factors seem to be the “low-hanging fruit”, or the first place to start, when we consider patients at the greatest risk and who can benefit the most from early diagnosis and treatment.
These and much more, including current and emerging treatment options, will be covered in this activity, which will aim to provide a comprehensive review of the evolving diagnostic and treatment landscape for NASH. The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
After completing this activity, the participant should be better able to:
- Explain NAFLD/NASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in NASH progression in order to improve the identification of NASH.
- Recognize current and emerging approaches and tools to screen and diagnose NAFLD and NASH in clinical practice.
- Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of NASH.
- Summarize the current guidelines and recommendations for treatment of NASH, including recent consensus statements.
- Review emerging NASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.
Robert H. Eckel, MD
Professor of Medicine, Emeritus
University of Colorado Anschutz Medical Campus
Dr. Eckel discloses the following:
Consultant, Advisor, Speaker: Amgen, Amarin, Arrowhead, The Better Company, Lexicon, The Healthy Aging Co, Weight Watchers International
Stephen A. Harrison, MD, FACP, FAASLD
Medical Director, Pinnacle Clinical Research
San Antonio, TX
Dr. Harrison discloses the following:
Principal Investigator of Grant Research: Akero Therapeutics, Inc., Axcella Health, Inc., Cirius Therapeutics, Inc., CiVi Biopharma Inc., Cymabay Therapeutics, Inc., Enyo Pharma S.A, Galectin Therapeutics, Inc., Gal med Research & Dev. LTD., Genfit Corp, Gilead Sciences, Inc., Hepion Pharmaceuticals, Inc., Hightide Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Metacrine Inc., NGM Biopharmaceuticals Inc., Northsea Therapeutics , Novartis Pharmaceuticals Corp, Novo Nordisk, Poxel, Sagimet Biosciences, Viking Therapeutics, Inc.
Consultant: AgomAB, Akero Therapeutics, Inc., Alentis Therapeutics AG, Alimentiv, Inc., Altimmune, Axcella Health, Inc., Boston Pharmaceuticals, B Riley FBR Inc., BVF Partners LP, Cohbar, Inc. Canfite, Corcept Therapeutics, Inc, Cymabay Therapeutics, Inc., Echosens North America Inc., Enyo Pharma S.A, Fibronostics, Foresite Labs, LLC, Fortress Biotech, Inc., Galectin Therapeutics, Inc., Genfit Corp, GNS, Hepion Pharmaceuticals Inc., Hightide Therapeutics, Inc., Histolndex PTE LTD, lnipharm, Intercept Pharmaceuticals, Inc., lonis, Kowa Research Institute, Inc., Madrigal Pharmaceuticals, Inc., Medpace, Inc. Metacrine Inc .. , Microba, NGM Biopharmaceuticals INC., Northsea Therapeutics B.V, Novo Nordisk, Nutrasource, Perspectum Diagnostics, Piper Sandler, Poxel, Prometic, Pharma SMT LTD, Ridgeline, Sagi met Biosciences, Sonic lncytes Medical Corp, Terns Inc., Viking Therapeutics, Inc.
Advisory Board / Panel: 89 Bio, Akero Therapeutics, Inc., Altimmune, Arrowhead, Axcella Health, Inc., Chronwell, CiVi, Cymabay Therapeutics, Inc., Echosens North America Inc., Foresite Labs, LLC, Galectin Therapeutics, Inc., Galmed Research & Dev. LTD, Genfit Corp, Gilead Sciences, Inc, Hepion Pharmaceuticals, Inc., Hightide Therapeutics, Inc., Histolndex PTE LTD, lndalo, Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Medpace Inc., Metacrine Inc., NGM Biopharmaceuticals., Northsea Therapeutics B.V, Novartis Pharmaceuticals, Novo Nordisk, PathAI, Poxel, Prometic Pharma SMT LTD, Ridgeline, Sagi met Biosciences, Sonic lncytes Medical Corp, Terns Inc., Theratechnologies
Publicly traded Stock / Shares (self-managed) and Stock Options: Akero Therapeutics, Inc., Chronwell Inc., Cirius Therapeutics, Inc, Galectin Therapeutics, Inc., Genfit Corp, Hepion Pharmaceuticals Inc., Histolndex PTE LTD, Metacrine Inc., NGM Biopharmaceuticals., Northsea Therapeutics B.V, Sonic lncytes Medical Corp
Diana Barb, MD
Clinical Associate Professor, University of Florida
Dr. Barb has no relevant financial relationship(s) with ineligible companies to disclose.
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Novo Nordisk.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-116-H01-P Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 2.0 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period April 5, 2023 through April 5, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 2.00 ABIM MOC and AMA PRA Category 1 Credit™
- 2.00 ACPE Pharmacy
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 CDE
- 2.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.